Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 10% carbamide peroxide significantly reduced acne lesions compared to a vehicle solution, suggesting it as an effective and safe alternative to benzoyl peroxide for treating mild to moderate acne.

This study found that a 10% carbamide peroxide solution significantly reduced acne lesions more effectively than a vehicle solution, suggesting it as a safe and effective alternative to benzoyl peroxide for treating mild to moderate acne.

Psoriasis patients experience moderate functional impairment related to disease severity and less satisfaction.

The document concludes that a unique target-like hair regrowth pattern in alopecia areata may be more common than thought and should be properly identified.

This paper discusses advancements in forensic hair analysis, emphasizing a novel DART–HRMS method that improves the accuracy and efficiency of detecting drug use timelines.

This article discusses the management of pruritic skin diseases in cats, focusing on diagnosis and the importance of client communication, but reports no new clinical results.

Hair restoration surgery is improving, with less painful techniques like FUE and robotic systems, but they can be costly and require training.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

Iron deficiency is not more common in women with hair loss, and neurogenic rosacea may need different treatment.

In men aged 40–60 years with androgenic alopecia, this study found that 1 mg/day finasteride reduced serum PSA concentrations by 40-50% after 48 weeks compared to placebo.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

People with facial disfigurements are judged more negatively, highlighting the social benefits of corrective surgery.

This study found that RADA-PRG hydrogels enhanced skin-derived precursor cell proliferation and improved hair follicle neogenesis in mice, suggesting potential use as a scaffold material in tissue engineering.

Antiyeast treatments work better for seborrheic dermatitis than steroids, and other findings include increased skin bacteria under plastic wrap, a nasal cell defect in Staphylococcus aureus carriers, quick resolution of certain skin reactions, high rubber latex allergy in spina bifida patients, and glyceryl monopentadecanoate's effectiveness for male hair loss.

Cimetidine is not a first-choice treatment for female hair loss, and there's no consistently successful treatment for this condition in men or normal hormone level women.

This article is a reply to Dr. Greenwald and does not provide new clinical results.

Finasteride's link to depression is questionable due to study flaws and potential bias.

In this study, health state utility values revealed a significant impact on quality of life for patients with alopecia areata, particularly those with more extensive hair loss.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study observed that patients with AA showed a high willingness to trade off lifespan for better disease-specific quality of life, indicating a significant disease burden.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

In this abstract, the authors provide an overview of the psychological impact of alopecia areata, highlighting how this autoimmune disorder can lead to reduced quality of life, increased anxiety and depression symptoms, and decreased work productivity due to hair loss and its social implications.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

This research highlights that engineered mice lacking the vitamin D receptor show multiple health issues similar to human vitamin D deficiency, underscoring the widespread impacts of the vitamin D endocrine system.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.